Evogene stock hits 52-week low at 2.6 amid market challenges - Investing.com
EVGN Stock | ILA 602.20 18.60 3.19% |
About 54% of Evogene's investors are presently thinking to get in. The analysis of current outlook of investing in Evogene suggests that some traders are interested regarding Evogene's prospects. The current market sentiment, together with Evogene's historical and current headlines, can help investors time the market. In addition, many technical investors use Evogene stock news signals to limit their universe of possible portfolio assets.
Evogene |
Evogene stock hits 52-week low at 2.6 amid market challenges Investing.com
Read at news.google.com
Evogene Fundamental Analysis
We analyze Evogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Evogene is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Evogene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Evogene stock to make a market-neutral strategy. Peer analysis of Evogene could also be used in its relative valuation, which is a method of valuing Evogene by comparing valuation metrics with similar companies.
Peers
Evogene Related Equities
CGEN | Compugen | 1.57 | ||||
BLRX | BioLine RX | 1.25 | ||||
KMDA | Kamada | 0.71 | ||||
ENLV | Enlivex Therapeutics | 0.98 | ||||
EVGN | Evogene | 4.73 |
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies |